<DOC>
	<DOCNO>NCT00823550</DOCNO>
	<brief_summary>This randomize , open label , phase IV , multicenter study efficacy safety lamivudine versus entecarvir therapy HBV-related advance liver disease patient high viral load normal slightly elevated transaminase .</brief_summary>
	<brief_title>Antiviral Therapy Hepatitis B Virus ( HBV ) -Related Advanced Liver Disease Patients</brief_title>
	<detailed_description>Currently , treatment guideline management chronic hepatitis B ( CHB ) recommend patient serum HBV DNA &gt; 105 copies/ml elevate ALT level great two time upper limit normal ( ULN ) obvious candidate antiviral therapy . Guidelines also suggest antiviral therapy consider CHB patient high viral load , biopsy show significant liver disease despite ALT ≤ 2× ULN . Data recent trial hepatitis B patient present normal minimally elevate ALT ( ≤ 2× ULN ) indicate significant hepatic pathology could still find . Serum ALT level may accurately predict activity liver damage . ALT poor predictor outcome therefore suitable criterion antiviral therapy chronic hepatitis B infection . Also , recent large randomize control clinical trial compare lamivudine maintenance placebo advance fibrosis ( Ishak fibrosis score ≥ 4 ) suggests sustain viral suppression antiviral therapy link reduce risk disease progression . ( Liaw YF et al . NEJM 2004 ; 351:1521-1531 )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion criterion Male female , 18 year age old HBsAg positive 6 month Serum HBV DNA &gt; 2,000 IU/ml Serum ALT &lt; 2 X ULN two consecutive occasion least 3 month apart Naïve nucleoside nucleotide therapy On liver biopsy , fibrosis score ≥ 3 accord METAVIR scoring system ( within 2 year Day 0 ) If liver biopsy available , subject must two follow item Overt finding cirrhosis radiologic evidence ( MRI , CT , US ) Gastrointestinal varix Platelet count &lt; 100,000 , Splenomegaly ( Spleen size 12cm ) The patient willing able provide write informed consent participate study Exclusion criteria A history SBP , variceal bleeding , HEP , HCC Decompensated liver disease ( ChildPugh score &gt; 10 ) Coinfected HCV HIV History form liver disease . Patient pregnant breastfeeding Treatment immunosuppressive , immunomodulatory agent antiviral agent within 6 month prior study entry A history liver transplantation plan liver transplantation A history medical disease condition would make patient unsuitable study . Patient currently abuse alcohol illicit drug history alcohol abuse illicit substance abuse within precede 2 year . Patient enrol plan enroll another clinical trial investigational agent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>Advanced fibrosis</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Entecavir</keyword>
</DOC>